Enhancing Perioperative Outcomes of Pancreatic Surgery with Wearable Augmented Reality Assistance System: A Matched-Pair Analysis
Objective:. The present study aimed to evaluate the safety of the first wearable augmented reality assistance system (ARAS) specifically designed for pancreatic surgery and its impact on perioperative outcomes. Background:. Pancreatic surgery remains highly complex and is associated with a high rate...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Health
2024-12-01
|
| Series: | Annals of Surgery Open |
| Online Access: | http://journals.lww.com/10.1097/AS9.0000000000000516 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Objective:. The present study aimed to evaluate the safety of the first wearable augmented reality assistance system (ARAS) specifically designed for pancreatic surgery and its impact on perioperative outcomes.
Background:. Pancreatic surgery remains highly complex and is associated with a high rate of perioperative complications. ARAS, as an intraoperative assistance system, has the potential to reduce these complications.
Methods:. This prospective, single-center study included 20 patients who underwent pancreatic surgery using ARAS. These patients were matched in a 1:3 ratio with 60 patients from our retrospective data who underwent standard pancreatic resection. Matching variables were selected based on factors associated with poor intraoperative outcomes.
Results:. A higher proportion of patients in the ARAS group were diagnosed with borderline resectable pancreatic cancer and received neoadjuvant chemotherapy (20.0% vs 6.7%, P = 0.085). Additionally, more patients in the ARAS group required arterial resection compared with the control group (15.0% vs 0.0%, P = 0.002). Nevertheless, the ARAS group had a significantly shorter operative time (246 vs 299 minutes, P = 0.004) and required significantly fewer intraoperative blood transfusions (0.0 ± 0.0 vs 0.5 ± 1.4 units, P = 0.014). None of the patients in the ARAS group had positive resection margins (0.0% vs 20.0%, P = 0.045). Furthermore, patients in the ARAS group experienced a significantly shorter hospital stay (13.8 ± 6.6 vs 17.9 ± 8.2 days, P = 0.046).
Conclusions:. ARAS is a safe and effective assistance system for pancreatic surgery, offering superior perioperative outcomes compared with standard procedures. |
|---|---|
| ISSN: | 2691-3593 |